phase i/ii, open-label, ongoing study of rilzabrutinib ...€¦ · 8. murrell d, et al. aad....
TRANSCRIPT
Presented at the virtual XXVIII Congress of the International Society on Thrombosis and Hemostasis (ISTH) on July 12-14, 2020
INTRODUCTIONImmune Thrombocytopenia (ITP)• ITP is characterized by immune-mediated platelet destruction and impairment of platelet production, leading to
thrombocytopenia, a predisposition to bleeding, and adverse impact on patient quality of life1
• Current therapies for adults with ITP include1,2
- Initial: intravenous immune globulin (IVIG), corticosteroids (CS) - Subsequent: splenectomy, thrombopoietin receptor agonists (TPO-RAs), rituximab, fostamatinib, and other immunosuppressive therapies (mycophenolate mofetil, cyclosporine)
• Unmet needs in relapsed or refractory ITP1,2
- Improve remission rates and durability - Avoid TPO-RA treatment-related rapid increase of platelet counts/thrombosis risk - Reduce or eliminate CS use - Provide tolerable and safe therapy that ensures good patient quality of life
Bruton Tyrosine Kinase (BTK)• BTK is an enzyme that plays a critical role in immune signaling pathways and is an essential signaling element
downstream of the B-cell, Fcγ, and Fcε receptors3,4 (Figure 1)
Figure 1. Bruton Tyrosine Kinase (BTK) Inhibition Targets Both Adaptive and Innate Drivers of Immune-Mediated Disease3,4
InnateAdaptive
BTK BTK
BTK
BTK
BTK
BTK
T cells B cells, plasma cells Monocytes, macrophages Mast cells, basophils Neutrophils
BTK inhibition
No effect
Blocks B-cell receptor
Inhibits plasma celldifferentiation and
antibody production
Blocks IgG-mediatedFcγR activation,
phagocytosis,inflammatory mediators
Blocks IgE-mediatedFcεR activation
and degranulation
Inhibits activation,adhesion, recruitment,
oxidative burst
BTK, Bruton tyrosine kinase; FcγR, Fcγ receptor; FcεR, Fcε receptor; Ig, immunoglobulin.
Rilzabrutinib (PRN1008)• Fully reversible, oral inhibitor targeting BTK and designed for immune-mediated diseases4,5 (Figure 2)• Covalent binding that achieves long BTK target engagement and durable inhibition with limited drug exposure5
• Provides potential clinical advantage based on rilzabrutinib’s rapid systemic clearance and long target residence time, which may prolong efficacy while reducing the potential for off-target toxicities4,5
• Rilzabrutinib does not alter platelet aggregation in blood taken from healthy volunteers or patients with ITP6 (Figure 3) - Contrasting significant effects on platelet aggregation observed with ibrutinib in healthy volunteers
Figure 2. Rilzabrutinib (PRN1008) is a Reversible, Covalent, Oral BTK Inhibitor With Durable BTK Occupancy and Low Systemic Exposure4,5
Selectivity
Precise Inhibition
Reversibility
Safety
Durable OccupancyWith Low Exposure
Efficacy
PK E
xpos
ure,
ng/
mL
Time, h
1000
500
0
BTK
Inhibition, %
100
80
60
40
20
00 5 10 15 20 25
Desired InhibitionRange
Occ
upan
cy in
vitr
o, %
Time, h
100
0
20
40
60
80
0 24
BTK
BMX
BLK
RLKTEC
COVALENTBINDING SITE
TARGETSITE
OFF-TARGETSITE
NON-COVALENT
BINDINGREGION
COVALENTBINDINGREGION
BLK, B-lymphoid tyrosine kinase; BMX, bone marrow kinase on chromosome X; BTK, Bruton tyrosine kinase; PK, pharmacokinetics; RLK, resting lymphocyte kinase; TEC, Tec protein tyrosine kinase.
Figure 3. Rilzabrutinib Does Not Impact Platelet Aggregation6,7
% M
axim
um A
ggre
gatio
n
150
100
50
0
5 µM TRAP
10 µM
ADP
1.5 m
g/mL R
istoc
etin
5 µM U
4661
9
5 µg/m
L Coll
agen
2.5 µg
/mL C
ollag
en
% M
axim
um A
ggre
gatio
n
% M
axim
um A
ggre
gatio
n
150
100
50
0
5 µM TRAP
10 µM
ADP
1.5 m
g/mL R
istoc
etin
5 µM U
4661
9
5 µg/m
L Coll
agen
2.5 µg
/mL C
ollag
en
150
100
50
0
5 µM TRAP
10 µM
ADP
1.5 m
g/mL R
istoc
etin
5 µM U
4661
9
5 µg/m
L Coll
agen
2.5 µg
/mL C
ollag
en
Ibrutinib has significant effects on platelet aggregation in healthy volunteers
1 µM Ibrutinib − Healthy Volunteers 1 µM Rilzabrutinib − Healthy Volunteers 1 µM Rilzabrutinib − ITP Patients
Rilzabrutinib does not alter platelet aggregation in blood taken from healthy volunteers or ITP patients
Platelet-rich plasma (PRP) was adjusted to 200,000-300,000 in healthy volunteers. Platelet count > 125,000 in ITP patients was required for inclusion in the study.
ADP, adenosine diphosphate; TRAP, thrombin receptor activating peptide.
PATIENTS AND METHODS• PRN1008-010 is a phase I/II adaptive, open-label, dose-finding study of oral rilzabrutinib in patients with relapsed
ITP (NCT03395210; EudraCT 2017-004012-19) • Patients with relapsed/refractory, primary or secondary ITP who had no other available treatment options were
enrolled (Table 1) - Platelet counts at study entry were < 30,000/µL
• Rilzabrutinib intrapatient dose-escalation treatment (Figure 4) - 3+3 study design
• If no responses were observed at a particular dose level in 3 patients from the sentinel cohort for 28 days, the dose was dropped and the next dose was considered the starting dose
• If response was seen at the low dose in 1 of 3 patients, then 3 more patients were added to the cohort - Oral rilzabrutinib was given initially with 200 and 400 mg qd doses, and then escalated to 300 and 400 mg bid doses - Dose escalations were allowed every 28 days up to the 400 mg bid dose - Stable concomitant CS or TPO-RA was allowed alongside rilzabrutinib treatment
Table 1. Patient Eligibility Criteria
Key Inclusion Criteria Key Exclusion Criteria• Adults aged 18 to 80 y with relapsed/refractory ITP• ITP that is primary or secondary to other diseases (eg, chronic
lymphocytic leukemia, systemic lupus erythematosus)• No other available/approved treatment options• ≥ 2 platelet counts < 30,000/µL at study entry • Adequate hematologic, hepatic, and renal function• Stable concomitant CS or TPO-RA was allowed
• Pregnant or lactating women• Treatment with rituximab or splenectomy within
3 months• Current drug or alcohol abuse• History of solid organ transplant• Positive screening for human immunodeficiency
virus, hepatitis B, or hepatitis C
Figure 4. Phase I/II Adaptive, Open-Label, Dose-Finding Study of Oral Rilzabrutinib in Relapsed/Refractory Immune Thrombocytopenia
Higher Dose
Continue atInitial DoseInitial Dose
Rilzabrutinib intrapatient dose escalation
• Doses* (24 wk): 200 and 400 mg qd, 300 and 400 mg bid• Oral treatment• 3+3 design• Focus on patients initiating 400 mg bid
Response
No response;escalate to higher dose
NCT03395210; EudraCT 2017-004012-19. bid, twice daily; qd, once daily. *Dose escalation part of the study was completed with all patients currently treated with the 400 mg bid dose.
Primary Endpoint• Two or more consecutive platelet counts ≥ 50,000/µL without requiring rescue medication
Additional Endpoints• Any 2 platelet counts ≥ 50,000/µL• Platelet responses over time, by duration of treatment, and clinical benefit (≥ 30,000/µL) • Stable response (platelet counts ≥ 50,000/µL at ≥ 50% visits for 4 of 8 last weeks of active treatment) • Safety
RESULTSPatient Demographics
Table 2. Patient Characteristics Were Similar Across All Rilzabrutinib Treatment Groups in a Difficult-to-Treat ITP Population
All Patients (N = 47) Initiated 400 mg bid (n = 32)
Median age, y (range) 50 (21-74) 50 (21-74)
Female, n (%) 27 (57) 20 (63)
ITP classification, n (%)
Primary ITP 44 (94) 31 (97)
Secondary ITP 3 (6) 1 (3)
Median duration of ITP, y (range) 7.8 (0.4-52.5) 7.3 (0.4-52.5)
Median baseline platelet count, × 109/L (range) 14 (3-33) 13 (4-33)
Median number of prior ITP therapies (range) 6 (1-54) 6 (1-54)
Splenectomy, n (%) 13 (28) 9 (28)
At least 1 prior ITP therapy 100% 100%Data cut-off 22Apr2020.
• Baseline patient characteristics and prior therapy were similar for the overall population and for patients who initiated rilzabrutinib 400 mg bid (Table 2)• Patients were heavily pretreated
-Median of 6 prior therapies -Median duration of ITP of 7+ years - 28% had undergone prior splenectomy
• 31 patients (66%) were on ≥ 1 concomitant ITP medication (CS and/or TPO-RA) and were considered inadequate responders
Efficacy• Oral rilzabrutinib treatment for ≥ 12 weeks further improved platelet responses (Table 3)
Table 3. Oral Rilzabrutinib Achieved Primary Endpoint in 50% Patients Treated ≥ 12 Weeks and Responses Were Maintained Over Time
Rilzabrutinib Duration and DosePatients Achieving Platelet Counts ≥ 50 × 109/L (80% CI)
Primary Endpoint* 2 Consecutive 50% of Counts 4 of Final 6 4 of Final 8
All patients enrolled (N = 47)≥ 12 wk (n = 36) Includes patients escalated to 400 mg bid
43% (34, 52)
50% (40, 60)
34% (26, 43)
39% (29, 50)
28% (20, 37)
33% (24, 44)
34% (26,43)
42% (32, 52)
Initiated 400 mg bid (n = 32)≥ 12 wk (initial 400 mg bid; n = 26)
44% (33, 55)50% (38, 62)
38% (27, 49)42% (31, 55)
31% (22, 42)35% (24, 47)
41% (30, 52)46% (34, 59)
Data as of 05May2020.*Primary endpoint was defined as 2 consecutive platelet counts ≥ 50,000/μL without requiring rescue medication.
Figure 5. Platelet Responses Had a Fast Onset and Were Maintained in the Majority of Patients Who Started on Rilzabrutinib 400 mg bid Dose
Plat
elet
Cou
nts
(× 1
09 /L)
Days
0
10
20
30
40
50
60
70
80
90
100100
200
300
400
-20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
Starting Dose 400 mg bid (n = 32)
Responded within 4 weeksRespondersNon-responders
Figure 6. Rilzabrutinib at All Doses and Treatment Times Achieved Significant, Consistent Responses Across Subgroups
43%
50%
40%
40%
44%
42%
0% 25% 50% 75% 100%
Primary Response (N = 47)
Completed ≥12 Wk Rilzabrutinib (n = 36)
Baseline Platelets ≤15K (n = 25)
Heavily Pretreated (≥4 Prior Therapies) (n = 38)
Rilzabrutinib Monotherapy(n = 16)
Rilzabrutinib + ConcomitantTherapy (n = 31)
Platelet ResponseData cut-off 22Apr2020. *Primary endpoint was defined as 2 consecutive platelet counts ≥ 50,000/μL without requiring rescue medication.
Safety• Median treatment duration (range)
- All patients: 17.7 wk (0.6-41.9) - 400 mg bid: 18.0 wk (1.4-24.6)
• Related treatment-emergent adverse events (TEAEs) were reported in 21 patients (45%); all were transient and grade 1 or 2 (Table 4) - No related serious adverse events (SAEs)
• No treatment-related bleeding or thrombotic events• No significant changes in the ITP-BAT bleeding scale from baseline to last visit • Safety profile is consistent with safety observed to date in pemphigus8
Table 4. Oral Rilzabrutinib Was Well Tolerated in ITP Patients
Related TEAEs* (≥ 10%), n (%)
All Patients (N = 47) Initiated 400 mg bid (n = 32)Grade 1 Grade 2 Grade 1 Grade 2
All related TEAEs 10 (21) 11 (23) 6 (19) 11 (34)Diarrhea 14 (30) 2 (4) 11 (34) 2 (6)Nausea 12 (26) 1 (2) 8 (25) 1 (3)Fatigue 5 (11) 1 (2) 3 (9) 1 (3)
Includes all data known by 05May2020. *Related TEAEs are reported by the maximum severity grade that was observed.
CONCLUSIONS
• 50% of patients achieved the primary endpoint response when initiated on rilzabrutinib 400 mg bid and treated for 12 weeks or more
• Rapid onset was seen in 53% of patients who initiated rilzabrutinib at 400 mg bid (platelet counts ≥ 30 × 109/L by the first week of treatment) and in 79% of responders
• Durable responses were achieved in the majority of responding patients
- 71% of weeks with ≥ 50 × 109/L platelets
- 88% of weeks with ≥ 20 × 109/L platelets above baseline
• Oral rilzabrutinib was well tolerated across all doses; all treatment-related TEAEs were mild to moderate with no thrombotic events and no bleeding events
REFERENCES1. Cooper N, Ghanima W. N Engl J Med. 2019;381:945-955. 2. Neunert C, Cooper N. Hematology Am Soc Hematol Educ Program. 2018;2018:568-575.3. López-Herrera G, et al. J Leukoc Biol. 2014;95:243-250. 4. Langrish C, et al. JID (ESDR). 2019;139:S216 (abstract 011). 5. Bradshaw JM, et al. Nat Chem Biol. 2015;11:525-531. 6. Langrish C, et al. Blood (ASH). 2017;130:suppl 1 (abstract 1052).7. Kuter DJ, et al. Blood (ASH). 2019;134:suppl 1 (abstract 87). Oral presentation.8. Murrell D, et al. AAD. 2018:LBA 10086.
CORRESPONDING AUTHOR
David KuterEmail: [email protected]
• Rilzabrutinib treatment led to platelet responses with a fast onset and responses that were maintained over time in the majority of patients who initiated rilzabrutinib 400 mg bid (Figure 5)
Fast onset• By day 8: platelets ≥ 30 × 109/L*
- 53% of patients initiating 400 mg bid - 79% of primary endpoint responders
• By week 4: 57% of responders achieved the primary endpoint†
Responses were maintained • Responders maintained platelet
counts for a median of - 71% of time (weeks) at ≥ 50 × 109/L - 88% of time (weeks) at ≥ 20 × 109/L above baseline
• Platelet responses were consistent overall and across subgroups (Figure 6)
• Overall, 43% of patients met the primary endpoint,* which increased with ≥12 weeks of rilzabrutinib
• Rilzabrutinib showed 15/38 (40%) heavily pretreated patients responding (≥ 4 prior therapies)
• Similar responses were achieved in patients receiving rilzabrutinib monotherapy (n=7/16) and inadequate responders on concomitant therapy (n=13/31)
ACKNOWLEDGEMENTSPatients, families, caregivers, and co-investigators who are participating in the rilzabrutinib ITP trial globallyPrincipia Biopharma Inc. for sponsoring the trial
BulgariaCzech Republic Netherlands Norway United Kingdom
Canada• Ontario• Quebec
USA• Illinois• Maryland• Massachusetts• Michigan• New York• North Carolina• Washington
Australia
50% (38, 62)
Data cut-off 22Apr2020.*Day 8 is the first platelet count taken after the start of treatment. †Primary endpoint was defined as 2 consecutive platelet counts ≥ 50,000/μL without requiring rescue medication.
Phase I/II, Open-Label, Ongoing Study of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Heavily Pretreated Immune Thrombocytopenia
David J. Kuter,1 Merlin Efraim,2 Jiri Mayer,3 Marek Trněný,4 Vickie McDonald,5 Robert Bird,6 Thomas Regenbogen,7 Mamta Garg,8 Zane Kaplan,9 Olga Bandman,10 Regan Burns,10 Ann Neale,10 Dolca Thomas,10 and Nichola Cooper11
1Massachusetts General Hospital Cancer Center, Boston, MA, USA; 2Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria; 3Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic; 4Charles University Hospital, Prague, Czech Republic; 5Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom; 6Princess Alexandra Hospital, Woolloongabba, Queensland, Australia;7MidMichigan Medical Center, Midland, MI, USA; 8Leicester Royal Infirmary, Leicester, United Kingdom; 9Monash Medical Centre, Clayton, Victoria, Australia;10Principia Biopharma Inc., South San Francisco, CA, USA; 11Department of Medicine, Hammersmith Hospital, London, United Kingdom
#PB1318